Yozo Kawano
- Cancer Research top 5%
- Cancer, Hypoxia, and Metabolism 3
- Cancer, Lipids, and Metabolism 3
- Oncology top 10%
- Pancreatic and Hepatic Oncology Research 3
- Immunology and Allergy top 10%
- Microbiology top 10%
-
- Lung Cancer Diagnosis and Treatment 6
- Lung Cancer Treatments and Mutations 6
- Tracheal and airway disorders 3
-
- Angiogenesis and VEGF in Cancer 5
- Glycosylation and Glycoproteins Research 3
Yozo Kawano
26 papers receiving 1.2k citations
Peers
Comparison fields: 5 of 87
- Cancer Research 362
- Oncology 435
- Immunology and Allergy 82
- Microbiology 8
- Pulmonary and Respiratory Medicine 331
Countries citing papers authored by Yozo Kawano
This map shows the geographic impact of Yozo Kawano's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yozo Kawano with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yozo Kawano more than expected).
Fields of papers citing papers by Yozo Kawano
This network shows the impact of papers produced by Yozo Kawano. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yozo Kawano. The network helps show where Yozo Kawano may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Yozo Kawano, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2009 | 41 | |
| 2 | DYRK2 expression may be a predictive marker for chemotherapy in non-small cell lung cancer. | 2009 | 30 |
| 3 | 2006 | 12 | |
| 4 | 2005 | 27 | |
| 5 | 2005 | 27 | |
| 6 | 2005 | 28 | |
| 7 | 2004 | 30 | |
| 8 | 2004 | 2 | |
| 9 | 2004 | 18 | |
| 10 | 2004 | 88 | |
| 11 | 2003 | 39 | |
| 12 | 2002 | 6 | |
| 13 | 2002 | 36 | |
| 14 | 2002 | 86 | |
| 15 | 2001 | 38 | |
| 16 | 2001 | 9 | |
| 17 | Evaluation of angiogenesis in non-small cell lung cancer: comparison between anti-CD34 antibody and anti-CD105 antibody. | 2001 | 226 |
| 18 | Expression of polysialic acid and STX, a human polysialyltransferase, is correlated with tumor progression in non-small cell lung cancer. | 2000 | 113 |
| 19 | 2000 | 45 | |
| 20 | 2000 | 0 |
About Yozo Kawano
Yozo Kawano is a scholar working on Microbiology, Cancer Research and Pulmonary and Respiratory Medicine, having authored 28 papers that have together received 1.2k indexed citations. Recurring topics across this work include Lung Cancer Diagnosis and Treatment (6 papers), Lung Cancer Treatments and Mutations (6 papers), Angiogenesis and VEGF in Cancer (5 papers), Glycosylation and Glycoproteins Research (3 papers), Cancer, Hypoxia, and Metabolism (3 papers), Cancer, Lipids, and Metabolism (3 papers), Tracheal and airway disorders (3 papers) and Pancreatic and Hepatic Oncology Research (3 papers). The work is most often cited by research in Cancer Research (362 citations), Oncology (435 citations) and Immunology and Allergy (82 citations). Yozo Kawano has collaborated with scholars based in Japan and France. Frequent co-authors include Hiromi Wada, Fumihiro Tanaka, Ryo Miyahara, Kazuhiro Yanagihara, Yosuke Otake, Mio Li, Shinya Ishikawa, Tatsuo Nakagawa, Nobuharu Hanaoka and Kazumasa Takenaka. Their work appears in journals such as Journal of Clinical Oncology, Clinical Cancer Research and International Journal of Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.